Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on liver cancer in new trial

NCT ID NCT06084884

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a therapy called AZD5851, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack liver cancer cells. The trial includes 94 adults with advanced or recurrent liver cancer that has not responded to standard treatments. Participants receive one infusion of these modified cells after a short course of chemotherapy to prepare their immune system. The main goals are to check safety and see if the treatment can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AZD5851 (a CAR-T cell therapy targeting GPC3)
What this could lead to
If it works, this could offer a new treatment option for people with advanced liver cancer that hasn't responded to other therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 94 participants, so results may not apply to everyone. CAR-T therapies can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

  • Research Site

    Phoenix, Arizona, 85054, United States

  • Research Site

    Duarte, California, 91010, United States

  • Research Site

    Orange, California, 92868, United States

  • Research Site

    San Francisco, California, 94143, United States

  • Research Site

    Washington D.C., District of Columbia, 20007, United States

  • Research Site

    Jacksonville, Florida, 32224, United States

  • Research Site

    Atlanta, Georgia, 30322, United States

  • Research Site

    Westwood, Kansas, 66205, United States

  • Research Site

    Rochester, Minnesota, 55905, United States

  • Research Site

    Hackensack, New Jersey, 07601, United States

  • Research Site

    New York, New York, 10065, United States

  • Research Site

    Columbus, Ohio, 43210, United States

  • Research Site

    Portland, Oregon, 97239, United States

  • Research Site

    Philadelphia, Pennsylvania, 19104, United States

  • Research Site

    Pittsburgh, Pennsylvania, 15237, United States

  • Research Site

    Kashiwa, 227-8577, Japan

  • Research Site

    Osakasayama-shi, 589-8511, Japan

  • Research Site

    Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.